Requests that the FDA determine whether the Reference Listed Drug (RLD) PEPCID RPD™ (famotidine) ORALLY DISINTEGRATING TABLETS, 20 mg and 40 mg; New Drug Application (NDA) 020752 of MERCK RESEARCH LABORATORIES DIV MERCK CO INC. has been voluntarily withdrawn from sale for safety or efficacy reasons | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-7178

Requests that the FDA determine whether the Reference Listed Drug (RLD) PEPCID RPD™ (famotidine) ORALLY DISINTEGRATING TABLETS, 20 mg and 40 mg; New Drug Application (NDA) 020752 of MERCK RESEARCH LABORATORIES DIV MERCK CO INC. has been voluntarily withdrawn from sale for safety or efficacy reasons

Documents

Comments

Description

Open

Key Dates

Comment Period OpensJun 30, 2026

Documents

Type	Title	Posted	Comments	Status
Supporting Material	Attachment 1 - Pepcid RPD NDA 20752 Discontinued 2002 Annual Ed.	Jun 30, 2026	--

Keywords

CDER

Citizen Petition

Lachman Consultant Services, Inc.

Requests that the FDA determine whether the

Reference Listed Drug (RLD)

PEPCID RPD™ (famotidine)

ORALLY DISINTEGRATING TABLETS, 20 mg and 40 mg

New Drug Application (NDA) 020752 of

Data from Regulations.gov